Management of Gastrointestinal Bleeding in Takayasu Arteritis – Evidence‑Based Recommendations

Immediate Assessment and Resuscitation

Target a hemoglobin level > 70 g/L in most patients and > 80 g/L in those with co‑existing cardiovascular disease when resuscitating acute GI bleed. 1
Perform diagnostic endoscopy within 24 hours of presentation after adequate preparation to locate the bleeding source. 1
In patients with hematochezia and hemodynamic instability, prioritize an upper endoscopy first to exclude an upper‑GI source. 1
Assess Takayasu disease activity at presentation by measuring ESR and CRP and performing a focused physical exam for pulse deficits, arterial bruits, and inter‑limb blood‑pressure differences. [2][3]

Obtain contrast‑enhanced CT or MR angiography of the thoracic and abdominal aorta with branch vessels to detect aneurysms, stenoses, or occlusions that may cause intestinal ischemia. [2][3]4
Consider mesenteric ischemia as a potential source of GI bleeding, especially when abdominal pain is present, because Takayasu frequently involves the abdominal aorta and mesenteric arteries in the “Indian” distribution pattern. [2][4]
Recognize geographic phenotypes: the “Japanese” type predominantly affects the thoracic aorta and great vessels, whereas the “Indian” type more often involves the abdominal aorta and renal arteries. [2][4]

Initiate high‑dose corticosteroids (e.g., prednisone 40–60 mg daily or equivalent) promptly when active Takayasu arteritis is confirmed or strongly suspected. [2][3]5
Add a non‑glucocorticoid immunosuppressive agent (methotrexate, azathioprine, or a TNF‑α inhibitor) to steroid therapy to reduce glucocorticoid toxicity and improve disease control. [5][6]
Monitor therapeutic response with serial physical examinations and repeat inflammatory markers (ESR or CRP). [2][3]

Apply endoscopic hemostatic techniques (thermal coagulation, sclerosant injection, or mechanical clips) for lesions with high‑risk stigmata such as active bleeding, visible vessels, or adherent clots. 1
Avoid epinephrine injection as a sole modality; combine it with another hemostatic method for adequate efficacy. 1

Class I, Level B recommendation: Delay elective revascularization procedures (angioplasty, bypass surgery) until the inflammatory state is treated and quiescent. [2][3]4
Do not perform elective vascular procedures during active inflammation, as outcomes are significantly poorer. [2][3]

Individualize antithrombotic strategies based on imaging findings and clinical complications rather than applying routine prophylaxis to all patients. 5

Inflammatory markers are elevated in only ~70 % of patients during the acute phase and ~50 % during the chronic phase; therefore, they should be interpreted alongside clinical assessment. [2][4]
Glucocorticoid monotherapy is associated with relapse rates approaching 70 % when adjunctive immunosuppression is omitted. [5][6]